Navigation Links
Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
Date:8/21/2012

An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. Khler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.

Both drugs are anti-CTLA-antibodies with similar mechanisms of action, but manufactured by different companies. Ipilimumab is an immunoglobulin G1 with a plasma half-life of 12-14 days. Tremelimumab is an immunoglobulin G2 with a plasma half-life of 22 days. Both have been extensively tested in metastatic melanoma and ipilimumab has been approved for use in patients with metastatic melanoma.

"During treatment with ipilimumab and tremelimumab, a unique set of adverse events may occur called 'immune-related adverse events,' or irAEs," said study lead author Jeffery S. Weber, M.D., Ph.D., director of Moffitt's Donald A. Adam Comprehensive Melanoma Research Center of Excellence. "These irAEs may include colitis, hepatitis, pancreatitis, lymphadenopathy, neuropathies and nephritis."

According to Weber, appropriate management of these side effects requires the cooperation of a multidisciplinary physician-led team that includes nurse practitioners and infusion nurses. Additionally, he recommends that specialists, including gastroenterologists, endocrinologists, hepatologists, dermatologists and surgeons, need education on managing these symptoms. Early recognition of irAEs and initiation of treatment are crucial, said Weber and his colleagues.

In their review of studies on the drugs' adverse effects, the researchers also found that irAEs correlated with treatment response in some studies. The reduction in tumor burden came in four different patterns after week 12 of treatment.

"Anti-CTLA-4 antibodies have shown patterns of anti-tumor response that are different from responses to conventional chemotherapy," explained Weber. "Because responses can occur slowly, or be mixed, 12 weeks has been the time to first evaluation with ipilimumab."

Weber and his colleagues also reviewed the new set of response criteria that have been created immune related response criteria or irRC to evaluate disease progression and benefit with immune checkpoint inhibitors like ipilimumab. The irRC criteria have been compared with modified WHO criteria in studies of patients receiving ipilimumab and can provide valuable information to oncologists as to when to stop treatment with ipilimumab, and when to continue.

"In this study, we provide a detailed description of irAEs and recommendations for practicing oncologists who are managing them along with the unusual kinetics of response associated with ipilimumab therapy," said Weber.


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
2. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
3. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
4. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
5. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
6. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
7. Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
8. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
9. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
10. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
11. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: